{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:13Z","timestamp":1791902593705,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA","award":["HO-18-19371"],"award-info":[{"award-number":["HO-18-19371"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40121-021-00468-w","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T08:02:54Z","timestamp":1624608174000},"page":"1607-1623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-1945","authenticated-orcid":false,"given":"Catherine","family":"Weil-Olivier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-3174","authenticated-orcid":false,"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7333-0567","authenticated-orcid":false,"given":"Corinne","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-2680","authenticated-orcid":false,"given":"St\u00e9phane","family":"Bou\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2022-9190","authenticated-orcid":false,"given":"Ekkehard","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-1742","authenticated-orcid":false,"given":"Emmanuel","family":"Aris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6397-7922","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Loncle-Provot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-0723","authenticated-orcid":false,"given":"Ga\u00eblle","family":"Nachbaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-0572","authenticated-orcid":false,"given":"C\u00e9line","family":"Pribil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"468_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","volume":"18","author":"R Acevedo","year":"2019","unstructured":"Acevedo R, Bai X, Borrow R, et al. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18:15\u201330.","journal-title":"Expert Rev Vaccines"},{"key":"468_CR2","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1016\/j.vaccine.2011.02.058","volume":"29","author":"LH Harrison","year":"2011","unstructured":"Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29:3363\u201371.","journal-title":"Vaccine"},{"key":"468_CR3","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","volume":"35","author":"R Whittaker","year":"2017","unstructured":"Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014. Vaccine. 2017;35:2034\u201341.","journal-title":"Vaccine"},{"key":"468_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41479-019-0062-0","volume":"11","author":"C Feldman","year":"2019","unstructured":"Feldman C, Anderson R. Meningococcal pneumonia: a review. Pneumonia (Nathan). 2019;11:3.","journal-title":"Pneumonia (Nathan)"},{"key":"468_CR5","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1017\/S0950268817000929","volume":"145","author":"O Sall","year":"2017","unstructured":"Sall O, Stenmark B, Glimaker M, et al. Clinical presentation of invasive disease caused by Neisseria meningitidis serogroup Y in Sweden, 1995 to 2012. Epidemiol Infect. 2017;145:2137\u201343.","journal-title":"Epidemiol Infect"},{"key":"468_CR6","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1086\/379719","volume":"37","author":"P Vienne","year":"2003","unstructured":"Vienne P, Ducos-Galand M, Guiyoule A, et al. The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis. 2003;37:1639\u201342.","journal-title":"Clin Infect Dis"},{"key":"468_CR7","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","volume":"59","author":"F Martinon-Torres","year":"2016","unstructured":"Martinon-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59:S12-20.","journal-title":"J Adolesc Health"},{"key":"468_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","volume":"10","author":"K Edmond","year":"2010","unstructured":"Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:317\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"468_CR9","doi-asserted-by":"publisher","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","volume":"27","author":"LH Harrison","year":"2009","unstructured":"Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51-63.","journal-title":"Vaccine"},{"key":"468_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, Muller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7:421\u201338.","journal-title":"Infect Dis Ther"},{"key":"468_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/INF.0000000000001048","volume":"35","author":"I Rivero-Calle","year":"2016","unstructured":"Rivero-Calle I, Vilanova-Trillo L, Pardo-Seco J, et al. The burden of pediatric invasive meningococcal disease in Spain (2008\u20132013). Pediatr Infect Dis J. 2016;35:407\u201313.","journal-title":"Pediatr Infect Dis J"},{"key":"468_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1586\/eri.13.42","volume":"11","author":"A Vyse","year":"2013","unstructured":"Vyse A, Anonychuk A, Jakel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11:597\u2013604.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"468_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40273-018-0679-5","volume":"36","author":"B Wang","year":"2018","unstructured":"Wang B, Santoreneos R, Afzali H, Giles L, Marshall H. Costs of invasive meningococcal disease: a global systematic review. Pharmacoeconomics. 2018;36:1201\u201322.","journal-title":"Pharmacoeconomics"},{"key":"468_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4161\/hv.7.1.13692","volume":"7","author":"KL Davis","year":"2011","unstructured":"Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vaccin. 2011;7:96\u2013101.","journal-title":"Hum Vaccin"},{"key":"468_CR15","doi-asserted-by":"publisher","first-page":"e0123383","DOI":"10.1371\/journal.pone.0123383","volume":"10","author":"M Tirani","year":"2015","unstructured":"Tirani M, Meregaglia M, Melegaro A. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. PLoS ONE. 2015;10:e0123383.","journal-title":"PLoS ONE"},{"key":"468_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","volume":"15","author":"C Wright","year":"2013","unstructured":"Wright C, Wordsworth R, Glennie L. Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia. Paediatr Drugs. 2013;15:49\u201358.","journal-title":"Paediatr Drugs"},{"key":"468_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jiph.2015.10.016","volume":"9","author":"S Benard","year":"2016","unstructured":"Benard S, Wright C, Voisine J, Olivier CW, Gaudelus J. Lifetime cost of meningococcal disease in France: scenarios of severe meningitis and septicemia with purpura fulminans. J Infect Public Health. 2016;9:339\u201347.","journal-title":"J Infect Public Health"},{"key":"468_CR18","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","volume":"37","author":"S Scholz","year":"2019","unstructured":"Scholz S, Koerber F, Meszaros K, et al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37:1692\u2013701.","journal-title":"Vaccine"},{"key":"468_CR19","doi-asserted-by":"publisher","first-page":"6885","DOI":"10.1016\/j.vaccine.2019.09.060","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Afzali HHA, Giles L, Marshall H. Lifetime costs of invasive meningococcal disease: a Markov model approach. Vaccine. 2019;37:6885\u201393.","journal-title":"Vaccine"},{"key":"468_CR20","doi-asserted-by":"crossref","unstructured":"Taha MK, Weil-Olivier C, Bouee S, et al. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2021:17(6):1858\u201366.","DOI":"10.1080\/21645515.2020.1849518"},{"key":"468_CR21","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","volume":"32","author":"JA Bettinger","year":"2013","unstructured":"Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32:e20\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"468_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11:774\u201383.","journal-title":"Lancet Neurol"},{"key":"468_CR23","volume-title":"Etude des algorithmes de d\u00e9finition de pathologies dans le syst\u00e8me national d\u2019information inter-r\u00e9gimes de l\u2019assurance maladie (SNIIRAM)","author":"C Quantin","year":"2015","unstructured":"Quantin C. Etude des algorithmes de d\u00e9finition de pathologies dans le syst\u00e8me national d\u2019information inter-r\u00e9gimes de l\u2019assurance maladie (SNIIRAM). Paris: Caisse nationale d\u2019Assurance maladie des travailleurs salari\u00e9s; 2015."},{"key":"468_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in england: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24:91\u2013104.","journal-title":"Value Health"},{"key":"468_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10198-017-0900-z","volume":"19","author":"G Saba","year":"2018","unstructured":"Saba G, Andrade LF, Gaillat J, et al. Costs associated with community acquired pneumonia in France. Eur J Health Econ. 2018;19:533\u201344.","journal-title":"Eur J Health Econ"},{"key":"468_CR26","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1080\/21645515.2015.1011957","volume":"11","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Gervais F, Gauthier A, Baptiste C, Martinon P, Bresse X. A comparative public health and budget impact analysis of pneumococcal vaccines: the French case. Hum Vaccin Immunother. 2015;11:2188\u201397.","journal-title":"Hum Vaccin Immunother"},{"key":"468_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10096-015-2542-3","volume":"35","author":"P Plans","year":"2016","unstructured":"Plans P, Munoz-Almagro C, Godoy P, Jane M, Carmona G. Clinical characteristics and pertussis costs in cases reported to epidemiological services and cases detected in household contacts in Catalonia (Spain). Eur J Clin Microbiol Infect Dis. 2016;35:285\u201392.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"468_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s004310050837","volume":"157","author":"G Tormans","year":"1998","unstructured":"Tormans G, Van Doorslaer E, van Damme P, Clara R, Schmitt HJ. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur J Pediatr. 1998;157:395\u2013401.","journal-title":"Eur J Pediatr"},{"key":"468_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119:964\u201379.","journal-title":"Health Policy"},{"key":"468_CR30","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1080\/21645515.2016.1160177","volume":"12","author":"R Gasparini","year":"2016","unstructured":"Gasparini R, Landa P, Amicizia D, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: a cost-effectiveness analysis. Hum Vaccin Immunother. 2016;12:2148\u201361.","journal-title":"Hum Vaccin Immunother"},{"key":"468_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12913-018-3066-1","volume":"18","author":"C Amand","year":"2018","unstructured":"Amand C, Tong S, Kieffer A, Kyaw MH. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Serv Res. 2018;18:294.","journal-title":"BMC Health Serv Res"},{"key":"468_CR32","doi-asserted-by":"publisher","first-page":"e0243529","DOI":"10.1371\/journal.pone.0243529","volume":"15","author":"V Pourcher","year":"2020","unstructured":"Pourcher V, Gourmelen J, Bureau I, Bouee S. Comorbidities in people living with HIV: an epidemiologic and economic analysis using a claims database in France. PLoS ONE. 2020;15:e0243529.","journal-title":"PLoS ONE"},{"key":"468_CR33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jinf.2017.02.011","volume":"74","author":"IP du Chatelet","year":"2017","unstructured":"du Chatelet IP, Deghmane AE, Antona D, et al. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006\u20132015. J Infect. 2017;74:564\u201374.","journal-title":"J Infect"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00468-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00468-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00468-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T10:48:38Z","timestamp":1627555718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00468-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00468-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}